Akero Therapeutics, Inc. — Director's Dealing 2021

Apr 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Akero Therapeutics, Inc. (AKRO)
CIK: 0001744659
Period of Report: 2021-04-01

Reporting Person: White William Richard (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-01	Common Stock	M	50000	$7.01	Acquired	52270	Direct
2021-04-01	Common Stock	S	48851	$28.6281	Disposed	3419	Direct
2021-04-01	Common Stock	S	1149	$29.2908	Disposed	2270	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-04-01	Stock Option (Right to Buy)	$7.01	M	50000	Disposed	2029-04-04	Common Stock (50000)	Direct

Footnotes

F1: Shares sold pursuant to a Rule 10b5-1 trading plan dated October 5, 2020, as amended on November 18, 2020 previously adopted by the Reporting Person.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $28.25 to $29.18, inclusive.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $29.25 to $29.35, inclusive.

F4: 25% of this option vested on April 1, 2020, and the remaining 75% of this option shall vest in 36 equal monthly installments thereafter.